MVRIX was selected for the 2025 DIPS 1000+ Project by the Ministry of SMEs and Startups and attended the official plaque ceremony on June 11.

The company’s Navibody platform—recognized as the basis for this selection—enables precise delivery by stably binding antibodies to LNPs encapsulating mRNA.

MVRIX will continue to enhance the technical maturity of its platform and deliver tangible results toward the commercialization of future therapeutic modalities, including in vivo CAR-T, gene therapies, and cancer vaccines.